MSS/ MMRp

我们是谁

  • 4 月 5, 2022
    在晚期实体瘤受试者中评估 MEDI5752 的研究
  • 4 月 5, 2022
    JS001 联合化疗对局部晚期结肠癌患者的疗效
  • 4 月 5, 2022
    A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
  • 4 月 5, 2022
    Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies
  • 4 月 5, 2022
    对转移性癌症患者施用经基因工程改造可表达对新抗原有反应的 T 细胞受体的自体 T 细胞
  • 4 月 5, 2022
    BMS-986253与Nivolumab或Nivolumab加Ipilimumab联合治疗晚期癌症的研究
  • 4 月 5, 2022
    晚期实体瘤患者BI 765063单药治疗及与BI 754091联合治疗试验
  • 4 月 5, 2022
    Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer
  • 4 月 5, 2022
    Neoadjuvant Safety of Sintilimab + XELOX + Bevacizumab in pMMR/MSS CRLM Patients
  • 4 月 5, 2022
    INNATE: Immunotherapy During Neoadjuvant Therapy for Rectal Cancer